Australian Red Cross Lifeblood


The Australian Red Cross Lifeblood, simply known as Lifeblood, is a branch of the Australian Red Cross responsible for the collection and distribution of blood and related products in Australia. Lifeblood employs around 3,700 employees across scientific, clinical and support services, processing over half a million non-remunerated blood donations each year. In November 2019, the division was renamed from the Australian Red Cross Blood Service to Australian Red Cross Lifeblood. Lifeblood is primarily funded by the Australian Government and states and territory governments.

History

The Red Cross's Australian blood services were initially managed by state-level organisations. Victoria's Blood Transfusion Service was founded in 1929, and by 1941 each state had its own Organ Transfusion Service. Also in 1941, the National Emergency Blood Transfusion Service was formed to coordinate the state groups. In 1945, the Red Cross took over blood and serum preparation units established by the Australian Army.
In 1995, a government report recommended the foundation of a separate national structure, and the ARCBS was formed in 1996, encompassing the old state and territory blood donation/transfusion services.
On 15 November 2019, what was formerly the Australian Red Cross Blood Service changed its name and branding to the Australian Red Cross Lifeblood, citing its increasing responsibility for non-blood products such as plasma, tissue, organs and breast milk.

Relationship with CSL

Australian Red Cross Lifeblood and its predecessors had a long-standing relationship with the Commonwealth Serum Laboratories, a government medical body founded in 1916. The Red Cross supplied CSL with donated blood for use in research and manufacture of medical products.
In 1994, CSL was privatised, becoming CSL Limited. The ARCBS continued to supply CSL with donated blood.

Infectious diseases

Blood donated in Australia has been tested for Hepatitis B since 1972, HIV-1 since 1985, Hepatitis C since 1990, HIV-2 since 1992/3, and HTLV-1 since 1993.
As with other blood transfusion services, the ARCBS has had to strike a balance between protecting blood recipients against infection, and accepting enough donors to maintain an adequate supply of blood. This has led to debate over which categories of potential donors should be excluded. For example, to protect against CJD, the ARCBS now refuses donations from anybody who lived in the United Kingdom for a total of six months or more between 1980 and 1996.
In 2003, a federal government report found that despite the introduction of Hepatitis C screening from February 1990, infected donors were told to keep donating until July of that same year; a total of 20,000 people were estimated to have been infected with Hepatitis C via blood products. Some infected blood was given to CSL and may have been used in thousands of CSL products, although it has not been shown that any of these products caused infection in the recipients.
The service has a policy of barring men who have had sex with men during the previous twelve months from donating blood. This has been the source of ongoing controversy, with a case referred to the Tasmanian Anti-Discrimination Commission. People who have engaged in heterosexual or female-to-female sex during the past 12 months are allowed to give blood. Female-to-female transmission is considered by the Centers for Disease Control to be rare. As well as deferring blood donations from MSM, other categories of sexual activity can also result in a 12-month deferral, such as sex with a prostitute or having a partner who has tested positive to hepatitis B or C.
In 2014, gay men again requested that the Australian Red Cross Blood Service permit them to donate blood. The Red Cross, in noting their concern, said they were receptive to a reduction in the current deferral period from 12 to 6 months. However, the Australian Therapeutic Goods Administration has rejected their submission on this issue, arguing that there would be a greater risk of HIV without a significant increase in blood supply. The Red Cross say they do not defer based on sexuality or relationships, but rather on sexual activity and for this reason it is not possible to deal with MSM on an individual basis.
In April 2020 the Therapeutic Goods Administration revised the deferral period for MSM down to three months. The revision requires approval of the federal, state and territory governments before it can go into effect.